Fact-check: the Endocrine Society podcast on compounded obesity medications

What the video covers

The host opens by disclosing that Eli Lilly supported the episode, then interviews Dr. Michael Weintraub of NYU Langone. He defines compounding with everyday examples, explains that compounders may prepare copies of a drug on the FDA shortage list, gives the dates the tirzepatide and semaglutide shortages were declared resolved, describes the market that grew during the shortage, and sets out the concerns: no FDA review of the product, salt forms and additives that were never in the trials, and dosing instructions in units, millilitres or milligrams with conversion charts and sometimes powders to reconstitute. He cites increases in poison-centre calls and in preparation errors, and argues that the underlying problem is the price of the approved drugs.

What it gets right

The regulatory account is accurate. Compounded drugs are not FDA approved; the FDA does not verify their safety, effectiveness or quality before sale; compounding of a shortage-listed drug is permitted under specific conditions; the FDA removed tirzepatide from the shortage list on 19 December 2024 and declared the semaglutide shortage resolved on 21 February 2025, with enforcement-discretion periods that then expired. The distinction between 503A pharmacies and 503B outsourcing facilities, and the history of sterility problems in the sector, are as the FDA describes them.

The dosing-confusion point is the most useful thing in the episode for a patient. A vial labelled in milligrams per millilitre, an insulin syringe marked in units and instructions written in a third unit are a recipe for ten-fold errors, and the FDA's own page reports overdoses from exactly that. Where a compounded product is used at all, the person needs the concentration, the prescribed dose in milligrams and a worked conversion in writing.

What it leaves out or overstates

The sponsorship matters. Lilly sells the approved tirzepatide products and has litigated against compounders; the host discloses the support, the guest does not mention it, and listeners should weigh the framing accordingly.

Three numbers are given without a source on air: up to 40 percent variance in drug content in tested compounded products, a roughly 1,500 percent rise in poison-centre calls about GLP-1 overdoses since 2019, and 49 percent higher odds of preparation errors in an adverse-event-report analysis. Each has a plausible origin (published assays of compounded vials, America's Poison Centers data widely reported in 2023 and 2024, and a FAERS analysis), but the episode does not name them and the figures cannot be checked from the transcript. Treat them as claims to verify, not facts to repeat.

The episode also does not acknowledge that the FDA permits compounding for an individual patient with a documented clinical need the approved product cannot meet, which is the basis on which some compounding continued after the shortage ended, or that the FDA has never suggested that every compounded product is substandard. Its concern is the absence of review, not a finding about each vial.

FormBlends dispenses compounded semaglutide and tirzepatide through licensed pharmacies. That is a direct commercial interest in this topic, disclosed here so you can read both the episode and this page with it in mind.

Where to go next

Compounding Explained covers 503A versus 503B, how to verify a pharmacy licence on a state board site and what a certificate of analysis shows. The units-to-milligram converters on FormBlends Calculators are built for exactly the conversion problem the episode describes, for medication a prescriber has already prescribed. The GLP-1 cost report at formblends.com compares brand self-pay programs with compounded pricing.